Regulation of p53 stability
Open Access
- 13 December 1999
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 18 (53), 7637-7643
- https://doi.org/10.1038/sj.onc.1203012
Abstract
Leading the way in imposing a policy of zero tolerance of cellular abnormalities that might lead to tumor development is the p53 protein. The efficiency of p53 in preventing cell growth is a strong deterrent to malignant progression, but this activity must be kept tightly restrained to allow normal cell growth and development. Essential components of this regulation are the mechanisms by which the p53 protein is degraded, and efficient turnover of p53 in normal cells prevents the accumulation of the protein. Modulation of these degradation pathways in response to stress leads to the rapid stabilization and accumulation of p53, and activation of the p53 response. It is now becoming clear that the Mdm2 protein is central to the regulation of p53 stability and multiple pathways exist through which the activity of Mdm2 can be inhibited. Defects in the ability to stabilize p53 are likely to contribute to malignant development, and restoration of this activity represents an extremely attractive possibility for tumor therapy.Keywords
This publication has 87 references indexed in Scilit:
- An Inhibitor of Nuclear Export Activates the p53 Response and Induces the Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated with the PODsExperimental Cell Research, 1999
- Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cellsInternational Journal of Cancer, 1999
- Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loopOncogene, 1999
- Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53The EMBO Journal, 1999
- DNA damage activates p53 through a phosphorylation–acetylation cascadeGenes & Development, 1998
- The Li-Fraumeni syndrome: An inherited susceptibility to cancerMolecular Medicine Today, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cellsOncogene, 1997
- Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transitionOncogene, 1997
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993